Pycnogenol® in chronic venous insufficiency and related venous disorders

Phytotherapy Research

Volumn 28, Issue 3, 2014, Pages 348-362

  Gulati, Om P ^a  

^a Horphag Research   (Switzerland)

Author keywords

chronic venous insufficiency; deep vein thrombosis; food supplement; haemorrhoids; long haul air travel; nutraceutical; post thrombotic syndrome; Pycnogenol; venous health; venous ulcers

Indexed keywords

ACETYLSALICYLIC ACID; AESCULUS HIPPOCASTANUM EXTRACT; ANTICOAGULANT AGENT; COLLAGEN; DAFLON; DIOSMIN; EVELLE; FIBRIN; GALACTOSAMINE; GINGER EXTRACT; HESPERIDIN; HISTAMINE; LEUKOTRIENE; MATRIX METALLOPROTEINASE; PLACEBO; PROSTAGLANDIN E2; PYCNOGENOL; REACTIVE OXYGEN METABOLITE; SEROTONIN; THROMBIN; TRACE ELEMENT; TROXERUTIN; UNCLASSIFIED DRUG; ZINOPIN;

ABSENCE OF SIDE EFFECTS; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD CLOTTING; CHRONIC VEIN INSUFFICIENCY; COLLAGEN DEGRADATION; COMPRESSION STOCKING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; ECZEMA; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE AGGREGATION; HEADACHE; HEMORRHOID; HUMAN; LEG EDEMA; MICROANGIOPATHY; MONOTHERAPY; MOTION SICKNESS; MUSCLE CRAMP; MUTAGENICITY; MYALGIA; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PATIENT COMPLIANCE; PINE; PINUS PINASTER; POSTTHROMBOSIS SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SKIN ULCER; STOMACH DISCOMFORT; THROMBOSIS; URTICARIA; VASODILATATION; VEIN DISEASE; VENOUS STASIS;

PINUS PINASTER;

CHRONIC VENOUS INSUFFICIENCY; DEEP VEIN THROMBOSIS; FOOD SUPPLEMENT; HAEMORRHOIDS; LONG-HAUL AIR TRAVEL; NUTRACEUTICAL; POST-THROMBOTIC SYNDROME; PYCNOGENOL; VENOUS HEALTH; VENOUS ULCERS;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; EDEMA; FLAVONOIDS; HEMORRHOIDS; HUMANS; PINUS; PLANT BARK; PLATELET AGGREGATION INHIBITORS; POSTTHROMBOTIC SYNDROME; VARICOSE ULCER; VASCULAR DISEASES; VASODILATOR AGENTS; VENOUS INSUFFICIENCY; VENOUS THROMBOSIS;

EID: 84895806058     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5019     Document Type: Review

References (85)

1. Araghi-Niknam M, Hosseini S, Larson D, et al,. 1999. Pine bark extract reduces platelet aggregation. Integr Med 2 (2): 73-77.
2. Arcangeli P,. 2000. Pycnogenol in chronic venous insufficiency. Fitoterapia 71 (3): 236-244.
3. Belcaro G, Cesarone MR, Errichi B, et al,. 2010. Pycnogenol treatment of acute hemorrhoidal episodes. Phytother Res 24 (3): 438-444.
4. Belcaro G, Cesarone MR, Errichi BM, et al,. 2005. Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 56 (6): 699-705.
5. Belcaro G, Cesarone MR, Rohdewald P, et al,. 2004. Prevention of venous thrombosis and thrombophlebitis in long-haul flights with pycnogenol. Clin Appl Thromb Hemost 10 (4): 373-377.
6. Belkhiri A, Richards C, Whaley M, et al,. 1997. Increased expression of activated matrix metalloproteinase-2 by human endothelial cells after sublethal H2O2 exposure. Lab Invest 77 (5): 533-539.
7. Bergan JJ,. 2005. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg. Angiology 56 (Suppl 1): S21-24.
8. Bergan JJ, Schmid-Schonbein GW,. 2000. Therapeutic management of chronic venous insufficiency: microcirculation as a target. Microcirculation 7 (6 Pt 2): S23-28.
9. Blazso G, Gabor M, Rohdewald P,. 1997. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 52 (5): 380-382.
10. Blazso G, Gabor M, Schonlau F, et al,. 2004. Pycnogenol accelerates wound healing and reduces scar formation. Phytother Res 18 (7): 579-581.
11. Blazso G, Gabor M, Sibbel R, et al,. 1994. Anti-inflammatory and superoxide radical scavenging activities of procyanidins containing extract from the bark of Pinus pinaster sol. and its fractions. Pharm Pharmacol Lett 3: 217-220.
12. Blazso G, Rohdewald P, Sibbel R, et al,. 1995. Anti-inflammatory activities of procyanidin-containing extracts from Pinus pinaster sol. Proceedings of the International Bioflavonoid Symposium, Vienna, Austria., Antus S, Gabor M, Vetschera K, (eds), July 16-19, 1995, 231-238.
13. Bollinger A, Jager K, Geser A, et al,. 1982. Transcapillary and interstitial diffusion of Na-fluorescein in chronic venous insufficiency with white atrophy. Int J Microcirc Clin Exp 1 (1): 5-17.
14. Borzelleca JF, Burdock GA, Thomas JA,. 2003. Opinion of an expert panel on the Generally Recognized As Safe (GRAS) status of French maritime pine bark extraxt (Pycnogenol®) as a flavoring agent. Internal Expert Report at Horphag Research, Geneva.
15. Cesarone MR, Belcaro G, Rohdewald P, et al,. 2005. Prevention of edema in long flights with Pycnogenol. Clin Appl Thromb Hemost 11 (3): 289-294.
16. Cesarone MR, Belcaro G, Rohdewald P, et al,. 2006a. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost 12 (2): 205-212.
17. Cesarone MR, Belcaro G, Rohdewald P, et al,. 2006b. Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study. Angiology 57 (5): 569-576.
18. Cesarone MR, Belcaro G, Rohdewald P, et al,. 2010. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine 17 (11): 835-839.
19. Cho KJ, Yun CH, Packer L, et al,. 2001. Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci 928: 141-156.
20. Devaraj, S, Vega-Lopez S, Kaul N, et al,. 2002. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 37 (10): 931-934.
21. Drehsen G,. 1999. From ancient pine bark uses to Pycnogenol. In Antioxidant Food Supplements in human health, Packer L, Hiramatsu M, Yoshikawa T, (eds). Academic Press: USA; 311-322.
22. Durackova Z, Trebaticky B, Novotny V, et al,. 2003. Lipid metabolism and erectile function improvement by Pycnogenol, extract from the bark of Pinus pinaster in patients suffering from erectile dysfunction- a pilot study. Nutr Res 23: 1189-1198.
23. Enseleit F, Sudano I, Périat D, et al,. 2012. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J 33 (13): 1589-97.
24. Errichi BM, Belcaro G, Hosoi M, et al,. 2011. Prevention of post thrombotic syndrome with Pycnogenol(R) in a twelve month study. Panminerva Med 53 (3 Suppl 1): 21-27.
25. Fitzpatrick DF, Bing B, Rohdewald P,. 1998. Endothelium-dependent vascular effects of Pycnogenol. J Cardiovasc Pharmacol 32 (4): 509-515.
26. Flore R, Gerardino L, Santoliquido A, et al,. 2007. Reduction of oxidative stress by compression stockings in standing workers. Occup Med (Lond) 57 (5): 337-341.
27. Flore R, Gerardino L, Santoliquido A, et al,. 2004. Enhanced oxidative stress in workers with a standing occupation. Occup Environ Med 61 (6): 548-550.
28. Grimm T, Schafer A, Hogger P,. 2004. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (pycnogenol). Free Radic Biol Med 36 (6): 811-822.
29. Gulati OP,. 1999. Pycnogenol® in venous disorders: A review. Eur Bull Drug Res 7 (2): 8-13.
30. Gulati OP,. 2005. The Nutraceutical Pycnogenol: its role in cardiovascular health and blood glucose control. Biomed Rev 16: 49-57.
31. Gulati OP,. 2008. Pycnogenol®-a nutraceutical for venous health. Biomed Rev 19: 33-43.
32. Gulati OP, Malmsten C, Ponard G, Gulati, N,. 1983a. The local edemogenic effects of leukotriene C4 and prostaglandin E2 in rats. Prostaglandins Leukot Med 10 (1): 11-17.
33. Gulati OP, Sharma SC, Hammersen F,. 1983b. Hemodynamic, biochemical and morphological changes in the dextran and D-galactosamine-induced edemas in rats. Arch Int Pharmacodyn Ther 263 (2): 272-287.
34. Hogg N, Kalyanaraman B, Joseph J, et al,. 1993. Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Lett 334 (2): 170-174.
35. Hosseini S, Lee J, Sepulveda RT, et al,. 2001. A randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res 21: 1251-1260.
36. Junger M, Hahn M, Klyscz T, et al,. 1999. Microangiopathy in the pathogenesis of chronic venous insufficiency. Curr Probl Dermatol 27: 124-129.
37. Junger M, Steins A, Hahn M, et al,. 2000. Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation 7 (6 Pt 2): S3-12.
38. Kim JCJ, Pinnas JL, Mooradian AD,. 2000. Effect of selected antioxidants on malondialdehyde modification of proteins. Nutrition 16: 1079-1081.
39. i chewing gum minimizes gingival bleeding and plaque formation. Phytomedicine 9: 410-413.
40. Koch R,. 2002. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res 16 (Suppl 1): S1-5.
41. Kohama T,. 2004. Nutritional supplements in clinical practice. Prog Med 24: 1503-1510.
42. Kohama T, Suzuki N, Ohno S, et al,. 2004. Analgesic efficacy of French maritime pine bark extract in dysmenorrhea: an open clinical trial. J Reprod Med 49 (10): 828-832.
43. Lau BHS, Riesen SK, Truong KP, et al,. 2004. Pycnogenol® as an adjunct in the management of childhood asthma. J Asthma 41 (8): 825-832.
44. Leu AJ, Leu HJ, Franzeck UK, et al,. 1995. Microvascular changes in chronic venous insufficiency-a review. Cardiovasc Surg 3 (3): 237-245.
45. Nelson AB, Lau BH, Ide N, et al,. 1998. Pycnogenol inhibits macrophage oxidative burst, lipoprotein oxidation, and hydroxyl radical-induced DNA damage. Drug Dev Ind Pharm 24 (2): 139-144.
46. Ni Z, Mu Y, Gulati OP,. 2002. Treatment of melasma with Pycnogenol. Phytother Res 16 (6): 567-571.
47. Nicolaides, AN,. 2000. Investigation of chronic venous insufficiency: A consensus statement (France, March 5-9, 1997). Circulation 102 (20): E126-163.
48. Nordmann H, Gulati OP,. 1983. Acute venous stasis and chronic venous insufficiency models in rats. Methods Find Exp Clin Pharmacol 5 (6): 347-355.
49. Nordmann H, Gulati OP,. 1984. Hemodynamic studies in acute venous stasis edema in rats. Experientia 40 (4): 346-348.
50. Nordmann HJ, Dumont JM, Gulati OP, et al,. 1984. Wirkungen von Venoruton® am Modell der akuten venösen Stauung an der Ratte. Swiss Med 6 (4a): 63-66.
51. Nuzum DS, Gebru TT, Kouzi SA,. 2010. Pycnogenol for chronic venous insufficiency. Am J Health Syst Pharm 68 (17): 1589-1590, 1599-1601.
52. Oliff H,. 2009. Scientific and clinical monograph on Pycnogenol. The American Botanical Council: USA.
53. Packer L, Rimbach G, Virgili F,. 1999. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, Pycnogenol. Free Radic Biol Med 27 (5/6): 704-724.
54. Peng Q, Wei Z, Lau BH,. 2000. Pycnogenol inhibits tumor necrosis factor-alpha-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 57 (5): 834-841.
55. Petrassi C, Mastromarino A, Spartera C,. 2000. Pycnogenol in chronic venous insufficiency. Phytomedicine 7 (5): 383-388.
56. Puruhito Y,. 2000. Pathophysiology of microcirculation in venous disease. Clin Hemorheol Microcirc 23 (2-4): 239-242.
57. Putter M, Grotemeyer KH, Wurthwein G, et al,. 1999. Inhibition of smoking-induced platelet aggregation by aspirin and pycnogenol. Thromb Res 95 (4): 155-161.
58. Ò in the treatment of venous insufficiency. Europ Bull Drug Res 12 (1): 7-12.
59. Rimbach G, Virgili F, Park YC, et al,. 1999. Effect of procyanidins from Pinus maritima on glutathione levels in endothelial cells challenged by 3-morpholinosydnonimine or activated macrophages. Redox Rep 4 (4): 171-177.
60. Rohdewald P,. 1998. PycnogenolIn Flavonoids in Health and Disease, Rice-Evans CA, Packer L, (eds). Marcel Dekker Inc.: New York; 405-419.
61. Rohdewald P,. 2002. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 40 (4): 158-168.
62. Rohdewald PJ,. 2005. Pycnogenol®, French Maritime Pine Bark Extract. Encyclopedia of Dietary Supplements. Marcel Dekker Inc.: New York; 545-553.
63. Rong Y, Li L, Shah V, et al,. 1994-1995. Pycnogenol protects vascular endothelial cells from t-butyl hydroperoxide induced oxidant injury. Biotechnol Ther 5 (3-4): 117-126.
64. Roseff SJ,. 2002. Improvement in sperm quality and function with French maritime pine tree bark extract. J Reprod Med 47 (10): 821-824.
65. Saliou C, Rimbach G, Moini H, et al,. 2001. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol Med 30 (2): 154-160.
66. Schmidtke I, Schoop W,. 1984. Das hydrostatische Ödem und seine medikamentöse Beeinflussung. Swiss Med 6 (4a): 67-69.
67. Schmidtke I, Schoop W,. 1995. Le pycnogénol: Thérapeutique médicamenteuse de l'oedème statique. Journal Suisse de médecine globale 3 (95): 114-115.
68. Scurr JH, Gulati OP,. 2004. Zinopin®- the Rationale of its use as a Food Supplement in Traveller's thrombosis and motion sickness. Phytother Res 18: 687-695.
69. Scurr, JH, Gulati OP,. 2005. Zinopin®- its use as a food supplement in traveller's thrombosis, oedema and motion sickness. Eur Bull Drug Res 13: 77-81.
70. Sharma SC, Gulati OP,. 1985. Role of calcium in the histamine release induced by D-galactosamine from rat mast cells. Experientia 41 (9): 1177-1178.
71. Sharma SC, Sharma S, Gulati OP,. 2003a. Pycnogenol® inhibits the release of histamine from mast cells. Phytotherapy Research 17: 66-69.
72. Ò prevents haemolytic injury in G6PD deficient human erythrocytes. Phytotherapy Research 17: 671-674.
73. Smith PD,. 1999. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 36 (Suppl 1): 24-36.
74. Stucker M, Falkenberg M, Reuther T, et al,. 2000. Local oxygen content in the skin is increased in chronic venous incompetence. Microvasc Res 59 (1): 99-106.
75. United States Pharmacopeial Convention I. 2007. Maritime Pine Extract. United States Pharmacopoeia-National Formulary. Rockville. USP 30-NF 25: 965-966.
76. Vinciguerra G, Belcaro G, Cesarone MR, et al,. 2006. Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology 57 (3): 331-339.
77. Virgili F, Kim D, Packer L,. 1998. Procyanidins extracted from pine bark protect alpha-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett 431 (3): 315-318.
78. Virgili F, Kobuchi H, Noda Y, et al,. 1999. Procyanidins from Pinus maritima bark: Antioxidant activity, effects on the immune system and modulation of nitrogen monoxide metabolism. In Antioxidant Food Supplements in human health, Packer L, Hiramatsu M, Yoshikawa T, (eds). Academic Press: New York 323-342.
79. Watson RR,. 1999. Reduction of cardiovascular disease risk factors by French Maritime Pine Bark Extract. Cardiovasc Rev Rep XX (VI): 326-329.
80. Wei ZH, Peng QL, Lau BHS,. 1997. Pycnogenol enhances endothelial cell antioxidant defenses. Redox Rep 3 (4): 219-224.
81. Wenner AH, Leu J, Spycher MA, et al,. 1980. Ultrastructural changes of capillaries in chronic venous insufficiency. Exp Cell Biol 48: 1-14.
82. Widmer LK, Stahelin HB, Nissen C, et al,. 1981. Venen- Arterienkrankheiten, Koronare Herzkrankheit bei Berufstätigen. Bern, Stuttgart, Wien: Verlag Hans Huber.
83. Wollina U, Abdel-Naser MB, Mani R,. 2006. A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. Int J Low Extrem Wounds 5 (3): 169-180.
84. Yao SK, Ober JC, Krishnaswami A, et al,. 1992. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 86 (4): 1302-1309.
85. Zhang D, Tao Y, Gao J, et al,. 2002. Pycnogenol in cigarette filters scavenges free radicals and reduces mutagenicity and toxicity of tobacco smoke in vivo. Toxicol Ind Health 18 (5): 215-224.